This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
It is planned to include 9 participants.
Actual study start date is June 18, 2022. The researchers expect to complete the study by March 30, 2024.
One primary outcome measure is to identify the dose-limiting toxicities (DLTs) of escalating doses of 177Lu-DOTA-EB-TATE up to 150 mCi.
Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT05475210.